Vancouver, British Columbia – TheNewswire – May 19, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP)(OTC:NSPDF) is pleased to announce that it has entered into a Letter of Intent with Vancouver based Biologic Pharmamedical Research (“Biologic”) to form a joint venture for the purpose of further developing and pursuing phase 2 clinical studies, utilizing one of Biologic’s patented technologies as a candidate for a potential COVID 19 treatment.
The joint venture entity will be granted certain rights from Biologic’s patents as it relates to applications for treating COVID 19 infections. The categories to be licensed will include, but are not limited to COVID 19 applications, as well as additional respiratory indications that may arise out of the fast-tracked phase 2 clinical trial.